Profile

William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Comprehensive Cancer Center
Brain Tumor Center of Excellence
Physiology & Pharmacology
Contact Information
Office:
336-716-6216
Fax:
336-716-0255
Email: bgmeiner@wakehealth.edu
Education & Training
  BA University of Chicago 1982
  PhD University of Utah 1989
  MBA Wake Forest University 2007
Fellowship University Alberta Medical School-Canada 1991
Memberships
American Association of Cancer Research
American Chemical Society
American Society of Pharmacology & Experimental Therapeutics
William Henry Gmeiner, Ph.D.

William Henry Gmeiner, Ph.D.

Professor, Cancer Biology
Comprehensive Cancer Center
Brain Tumor Center of Excellence
Physiology & Pharmacology
Contact Information
Office:
336-716-6216
Fax:
336-716-0255
Email: bgmeiner@wakehealth.edu
Research Interests
biotechnology , cancer/oncogenesis , drugs/therapeutic agents pharm , neurosciences/behavior
Recent Publications
Gmeiner WH. Carbon nanotubes for cancer therapy. In: Kumar CSSR, ed. Carbon nanomaterials. Weinheim (Germany): Wiley-VCH; 2011: 309-332.

Ghosh S, Salsbury FR Jr, Horita DA, Gmeiner WH. Zn2+ selectively stabilizes FdU-substituted DNA through a unique major groove binding motif. Nucleic Acids Res. 2011; 39(10):4490-4498.

Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA. The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs. J Nucleic Acids. 2011; 2011():631372.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Blood. 2011; 118(21):1109-1110.

Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther. 2010; 9(12):3105-3114.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Blood. 2010; 116(21):1353.

Ghosh S, Dutta S, Gomes E, Carroll D, D'Agostino R Jr, Olson J, Guthold M, Gmeiner WH. Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. ACS Nano. 2009; 3(9):2667-2673.

Gmeiner WH, Hellmann GM, Shen P. Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Oncol Rep. 2008; 19(1):245-251.

Gmeiner WH, Garg S, Hatcher HC, Smith TL, Bourland JD, Garg PK. MicroPET imaging to monitor tumor response to single agent and combined ionizing radiation therapy and FdUMP treatment [abstract]. J Nucl Med. 2007; 48(6 Suppl 2):83P.

Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep. 2007; 18(1):287-291.

Gmeiner WH. Genetic determinants for activated fluoropyrimidine chemotherapy. Drug Dev Res. 2006; 67(2):119-129.
All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Back To Top
Last Updated 4/30/2012
Quick Reference
Request an Appointment
New Patients
336-716-WAKE
888-716-WAKE
Existing patients may contact the clinic directly.
Locate Faculty

e.g., "allergy," "diabetes"

US News Best Hospital AwardANCC Magnet Association AwardBest Doctors 2011-2012 AwardConsumer Choice #1 Award 2011-2102US News Best Medical Schools 2011 Award

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.